
CytoSorbents (CTSO) Stock Forecast & Price Target
CytoSorbents (CTSO) Analyst Ratings
Bulls say
CytoSorbents Corp has reported a 10% increase in product revenues year-over-year, reaching $9.5 million, with gross margins exceeding 70%, reflecting improved geographic mix and manufacturing efficiencies. The company has demonstrated significant growth in global distributor sales, which rose 14.4% year-over-year, while direct sales outside Germany experienced a robust 23.5% increase. Additionally, advancements in the DrugSorb ATR product and supportive clinical publications bolster the company's outlook by enhancing its evidence base and market potential.
Bears say
CytoSorbents Corp's revenue projections have been revised downward for both 2025 and 2026, reflecting ongoing challenges in commercial sales within Germany, which is critical to the company's revenue growth. The negative outlook is further exacerbated by management's indication of patient imbalances in the initial U.S. commercial launch, which raises concerns about market acceptance and sales performance. Additionally, despite a distressed valuation that seems detached from fundamentals, the company's financial forecasts suggest potential difficulties in attaining growth targets amid a constrained revenue environment.
This aggregate rating is based on analysts' research of CytoSorbents and is not a guaranteed prediction by Public.com or investment advice.
CytoSorbents (CTSO) Analyst Forecast & Price Prediction
Start investing in CytoSorbents (CTSO)
Order type
Buy in
Order amount
Est. shares
0 shares